Skip to Main Content

Advertisement

Skip Nav Destination

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

December 30, 2021
Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory heavily pretreated multiple myeloma. Read more about SIRIUS here.  

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X